Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Jonak

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
The British Journal of Dermatology|May 21, 2021
Single-cell RNA sequencing profiling in a patient with discordant primary cutaneous B-cell and T-cell lymphoma reveals micromilieu-driven immune skewingC Jonak, N Alkon, K Rindler, et al.
Scientific Reports|March 27, 2024
Author Correction: Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA)T Graier, W Weger, C Jonak, et al.
Scientific Reports|September 5, 2022
Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA)T Graier, W Weger, C Jonak, et al.
The British Journal of Dermatology|June 17, 2021
Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivityE Papadavid, E Kapniari, V Pappa, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 20, 2020
Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicentre studyM-C Brüggen, J Valencak, R Stranzenbach, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 27, 2024
Health-related quality of life and its influencing factors in patients with primary cutaneous B-cell lymphomas: A multicentric study in 100 patientsA E C Schirren, J D Albrecht, S Melchers, et al.
The British Journal of Dermatology|December 8, 2020
Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysisT Graier, W Salmhofer, C Jonak, et al.
The British Journal of Dermatology|May 4, 2019
Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) studyK Molloy, C Jonak, F J S H Woei-A-Jin, et al.
The British Journal of Dermatology|June 24, 2020
Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international studyE Hodak, S Sherman, E Papadavid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 28, 2018
Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International ConsortiumP Quaglino, M Maule, H M Prince, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
The British Journal of Dermatology|May 21, 2021
Single-cell RNA sequencing profiling in a patient with discordant primary cutaneous B-cell and T-cell lymphoma reveals micromilieu-driven immune skewingC Jonak, N Alkon, K Rindler, et al.
Scientific Reports|March 27, 2024
Author Correction: Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA)T Graier, W Weger, C Jonak, et al.
Scientific Reports|September 5, 2022
Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA)T Graier, W Weger, C Jonak, et al.
The British Journal of Dermatology|June 17, 2021
Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivityE Papadavid, E Kapniari, V Pappa, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 20, 2020
Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospective multicentre studyM-C Brüggen, J Valencak, R Stranzenbach, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 27, 2024
Health-related quality of life and its influencing factors in patients with primary cutaneous B-cell lymphomas: A multicentric study in 100 patientsA E C Schirren, J D Albrecht, S Melchers, et al.
The British Journal of Dermatology|December 8, 2020
Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysisT Graier, W Salmhofer, C Jonak, et al.
The British Journal of Dermatology|May 4, 2019
Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) studyK Molloy, C Jonak, F J S H Woei-A-Jin, et al.
The British Journal of Dermatology|June 24, 2020
Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international studyE Hodak, S Sherman, E Papadavid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 28, 2018
Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International ConsortiumP Quaglino, M Maule, H M Prince, et al.
Pageof 4